Jessica Kirshner PhD

Jessica Kirshner is a Senior Director of Oncology at Regeneron Pharmaceuticals and leads a team of scientists responsible for discovering and developing immune-oncology therapeutics. Her team focuses on developing CD3-bispecific antibodies and antibody-drug conjugates for various tumor indications and is active in Regeneron’s CAR T cell collaborations. She has led three programs from discovery to first in human studies: REGN1979, targeting CD20 on lymphoid malignancies; REGN4018, targeting MUC16 in ovarian cancer; and REGN5458, targeting BCMA in multiple myeloma. During her career, she has focused on target validation, drug discovery, and drug development. Dr. Kirshner earned her Ph.D. in Biomedical Sciences at UCSF and subsequently performed post-doctoral work on tumor virology at Harvard Medical School. She has authored numerous publications and is an inventor on multiple filed and issued the US and international patents.